Display title | Biology:Oncolytic AAV |
Default sort key | Oncolytic AAV |
Page length (in bytes) | 10,478 |
Namespace ID | 3026 |
Namespace | Biology |
Page ID | 29234 |
Page content language | en - English |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Counted as a content page | Yes |
HandWiki item ID | None |
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Page creator | imported>JMinHep |
Date of page creation | 21:42, 11 February 2024 |
Latest editor | imported>JMinHep |
Date of latest edit | 21:42, 11 February 2024 |
Total number of edits | 1 |
Recent number of edits (within past 90 days) | 0 |
Recent number of distinct authors | 0 |
Description | Content |
Article description: (description ) This attribute controls the content of the description and og:description elements. | Adeno-associated virus (AAV) has been researched as a viral vector in gene therapy for cancer treatment as an Oncolytic Virus. Currently there are not any FDA approved AAV cancer treatments, as the first FDA approved AAV treatment was approved December 2017. However, there are many Oncolytic AAV applications... |